Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Buy
52
USPH Quote, Financials, Valuation and Earnings
Last price:
$91.21
Seasonality move
:
2.46%
Day range:
$89.72 - $93.40
52-week range:
$76.18 - $113.63
Dividend yield:
1.93%
P/E ratio:
53.71x
P/S ratio:
2.13x
P/B ratio:
2.86x
Volume:
244.2K
Avg. volume:
117.2K
1-year change:
-1.85%
Market cap:
$1.4B
Revenue:
$604.8M
EPS (TTM):
$1.70
Analysts' Opinion
-
Consensus RatingUS Physical Therapy has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, US Physical Therapy has an estimated upside of 21.93% from its current price of $91.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $91.31.
Fair Value
-
According to the consensus of 0 analysts, US Physical Therapy has 21.93% upside to fair value with a price target of -- per share.
USPH vs. S&P 500
-
Over the past 5 trading days, US Physical Therapy has underperformed the S&P 500 by -0.32% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
US Physical Therapy does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
US Physical Therapy has grown year-over-year revenues for 14 quarters straight. In the most recent quarter US Physical Therapy reported revenues of $168M.
Earnings Growth
-
US Physical Therapy earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter US Physical Therapy reported earnings per share of $0.39.
Enterprise value:
1.6B
EV / Invested capital:
1.96x
Price / LTM sales:
2.13x
EV / EBIT:
31.86x
EV / Revenue:
2.47x
PEG ratio (5yr expected):
--
EV / Free cash flow:
21.67x
Price / Operating cash flow:
18.70x
Enterprise value / EBITDA:
23.73x
Gross Profit (TTM):
$121.9M
Return On Assets:
1.09%
Net Income Margin (TTM):
1.72%
Return On Equity:
1.67%
Return On Invested Capital:
1.37%
Operating Margin:
8.78%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $541.8M | $591.2M | $645.7M | $150M | $168M | |
| Gross Profit | $111.4M | $118.8M | $121.9M | $27.9M | $29.1M | |
| Operating Income | $71.1M | $69.3M | $65.3M | $15.9M | $14.7M | |
| EBITDA | $87.2M | $78.7M | $67.1M | $21.8M | $18.7M | |
| Diluted EPS | $2.99 | $1.72 | $1.70 | $0.51 | $0.39 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $82.6M | $79.4M | $112.9M | $228.5M | $204.9M | |
| Total Assets | $575.4M | $630.1M | $799.7M | $1B | $1B | |
| Current Liabilities | $93.2M | $81.7M | $81.5M | $82.4M | $115.3M | |
| Total Liabilities | $169.8M | $201.3M | $332.9M | $342M | $358.5M | |
| Total Equity | $405.7M | $428.8M | $466.8M | $668.2M | $670.7M | |
| Total Debt | $12.5M | $35.9M | $154.2M | $149.1M | $142.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $57.1M | $72.4M | $82.4M | $16.4M | $22.1M | |
| Cash From Investing | -$117.8M | -$80M | -$63M | -$16.9M | -$5.8M | |
| Cash From Financing | $79.3M | $117.3M | -$50.1M | -$12.5M | -$12.2M | |
| Free Cash Flow | $47.6M | $64.4M | $73.4M | $13.8M | $19.6M | |
USPH
Sector
Market Cap
$1.4B
$44.6M
Price % of 52-Week High
80.36%
45.71%
Dividend Yield
1.93%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-1.85%
-29.09%
Beta (5-Year)
1.463
0.772
Dividend yield:
1.93%
Annualized payout:
$1.72
Payout ratio:
237.3%
Growth streak:
3 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$93.61
200-day SMA
Sell
Level
$94.31
Bollinger Bands (100)
Buy
Level
81.48 - 93.84
Chaikin Money Flow
Buy
Level
21.6M
20-day SMA
Sell
Level
$96.20
Relative Strength Index (RSI14)
Sell
Level
42.17
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-86.1438
50-day SMA
Buy
Level
$90.32
MACD (12, 26)
Buy
Level
0.25
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
16M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.7004)
Buy
CA Score
(Annual)
Level (-0.26)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.3096)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
Stock Forecast FAQ
In the current month, USPH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The USPH average analyst price target in the past 3 months is --.
-
Where Will US Physical Therapy Stock Be In 1 Year?
According to analysts, the consensus estimate is that US Physical Therapy share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About US Physical Therapy?
Analysts are divided on their view about US Physical Therapy share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that US Physical Therapy is a Sell and believe this share price will drop from its current level to --.
-
What Is US Physical Therapy's Price Target?
The price target for US Physical Therapy over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is USPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for US Physical Therapy is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of USPH?
You can purchase shares of US Physical Therapy via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase US Physical Therapy shares.
-
What Is The US Physical Therapy Share Price Today?
US Physical Therapy was last trading at $91.21 per share. This represents the most recent stock quote for US Physical Therapy. Yesterday, US Physical Therapy closed at $91.31 per share.
-
How To Buy US Physical Therapy Stock Online?
In order to purchase US Physical Therapy stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
